Standard BioTools (LAB) Projected to Post Earnings on Tuesday

Standard BioTools (NASDAQ:LAB) is anticipated to post its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Standard BioTools to post earnings of ($0.03) per share and revenue of $18.50 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:00 PM ET.

Standard BioTools Price Performance

Shares of Standard BioTools stock opened at $1.13 on Friday. The stock has a market capitalization of $434.56 million, a P/E ratio of -3.32 and a beta of 1.29. The business has a 50 day simple moving average of $1.40 and a two-hundred day simple moving average of $1.34. Standard BioTools has a 12 month low of $0.92 and a 12 month high of $1.72.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on LAB. Weiss Ratings restated a “sell (d-)” rating on shares of Standard BioTools in a report on Thursday, January 22nd. Wall Street Zen cut shares of Standard BioTools from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. TD Cowen lowered their price target on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research report on Wednesday, November 5th. Finally, Zacks Research raised shares of Standard BioTools to a “hold” rating in a research note on Thursday, December 11th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Standard BioTools presently has a consensus rating of “Reduce” and a consensus price target of $1.35.

Insider Transactions at Standard BioTools

In other news, Director Casdin Partners Master Fund, L bought 150,000 shares of Standard BioTools stock in a transaction on Thursday, December 4th. The shares were bought at an average cost of $1.45 per share, with a total value of $217,500.00. Following the completion of the purchase, the director directly owned 72,100,000 shares of the company’s stock, valued at approximately $104,545,000. This trade represents a 0.21% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have bought 8,050,000 shares of company stock worth $10,532,500 in the last ninety days. 23.16% of the stock is currently owned by company insiders.

Institutional Trading of Standard BioTools

Several institutional investors have recently made changes to their positions in LAB. Mak Capital One LLC grew its position in Standard BioTools by 21.1% in the fourth quarter. Mak Capital One LLC now owns 19,288,158 shares of the company’s stock worth $24,689,000 after acquiring an additional 3,356,352 shares during the period. Vanguard Group Inc. raised its position in Standard BioTools by 1.6% in the third quarter. Vanguard Group Inc. now owns 17,245,583 shares of the company’s stock valued at $22,419,000 after purchasing an additional 263,845 shares during the period. State Street Corp lifted its stake in shares of Standard BioTools by 1.3% in the 4th quarter. State Street Corp now owns 6,482,766 shares of the company’s stock valued at $8,298,000 after purchasing an additional 80,117 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Standard BioTools by 133.0% during the 4th quarter. Millennium Management LLC now owns 3,387,428 shares of the company’s stock worth $4,336,000 after purchasing an additional 1,933,853 shares during the period. Finally, ARK Investment Management LLC increased its position in shares of Standard BioTools by 1.5% during the 4th quarter. ARK Investment Management LLC now owns 3,066,665 shares of the company’s stock worth $3,925,000 after purchasing an additional 44,937 shares during the last quarter. Hedge funds and other institutional investors own 53.74% of the company’s stock.

About Standard BioTools

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.